Hyperlipidemia Management: Comprehensive Review and Looking Forward

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Statins are the primary treatment, but some patients need additional therapies due to insufficient response or intolerance.
• Personalized, patient-centered approaches are increasingly emphasized in lipid management.

Purpose of the Study:

• To review recent advancements in lipid metabolism research.
• To explore adjunctive therapies for hyperlipidemia beyond statins.
• To highlight agents that improve cardiovascular outcomes.

Main Methods:

• Literature review of recent advancements in lipid metabolism.
• Analysis of clinical data on adjunctive lipid-lowering agents.
• Synthesis of evidence on efficacy and cardiovascular outcomes.

Main Results:

• Emerging agents like PCSK9 inhibitors, ezetimibe, bempedoic acid, and inclisiran show significant efficacy.
• These therapies effectively lower low-density lipoprotein cholesterol (LDL-C).
• Adjunctive treatments contribute to improved cardiovascular outcomes.

Conclusions:

• Recent lipid metabolism research has identified effective adjunctive therapies for hyperlipidemia.
• These agents provide valuable options for patients not adequately managed by statins alone.
• Personalized treatment strategies incorporating these advancements can optimize cardiovascular risk reduction.